Emmaus Life Sciences Inc
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age… Read more
Emmaus Life Sciences Inc (EMMA) - Net Assets
Latest net assets as of September 2025: $-59.49 Million USD
Based on the latest financial reports, Emmaus Life Sciences Inc (EMMA) has net assets worth $-59.49 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($20.76 Million) and total liabilities ($80.24 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-59.49 Million |
| % of Total Assets | -286.61% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 157.51 |
Emmaus Life Sciences Inc - Net Assets Trend (1999–2024)
This chart illustrates how Emmaus Life Sciences Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Emmaus Life Sciences Inc (1999–2024)
The table below shows the annual net assets of Emmaus Life Sciences Inc from 1999 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-56.48 Million | -18.27% |
| 2023-12-31 | $-47.76 Million | -40.08% |
| 2022-12-31 | $-34.09 Million | -58.93% |
| 2021-12-31 | $-21.45 Million | -295.83% |
| 2020-12-31 | $-5.42 Million | +50.97% |
| 2019-12-31 | $-11.05 Million | -436.32% |
| 2018-12-31 | $3.29 Million | -27.73% |
| 2017-12-31 | $4.55 Million | +1872.87% |
| 2016-12-31 | $-256.50K | +94.70% |
| 2015-12-31 | $-4.84 Million | -174.55% |
| 2014-12-31 | $-1.76 Million | +18.44% |
| 2013-12-31 | $-2.16 Million | +83.48% |
| 2012-12-31 | $-13.07 Million | -14.47% |
| 2011-12-31 | $-11.42 Million | -171.66% |
| 2010-12-31 | $-4.20 Million | -278.73% |
| 2009-12-31 | $-1.11 Million | -205.43% |
| 2008-12-31 | $1.05 Million | -80.33% |
| 2007-12-31 | $5.35 Million | +2565.51% |
| 2006-12-31 | $-217.12K | -737.52% |
| 2003-12-31 | $-25.92K | -63.39% |
| 2002-12-31 | $-15.87K | -35.23% |
| 2001-12-31 | $-11.73K | -699.80% |
| 2000-12-31 | $-1.47K | -- |
| 1999-12-31 | $0.00 | -- |
Equity Component Analysis
This analysis shows how different components contribute to Emmaus Life Sciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 26178500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $206.10 Million | % |
| Total Equity | $-56.48 Million | 100.00% |
Emmaus Life Sciences Inc Competitors by Market Cap
The table below lists competitors of Emmaus Life Sciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Uniinfo Telecom Services Limited
NSE:UNIINFO
|
$712.35K |
|
Hestia Insight Inc
OTCQB:HSTA
|
$712.45K |
|
BOOZ ALLEN HAM-A
BE:BZ9
|
$712.46K |
|
Coreo AG
F:CORE
|
$712.58K |
|
SYROS PHARMAC.NEW DL-001
F:0S90
|
$712.24K |
|
Giant Motorsports Inc
PINK:BZRD
|
$712.16K |
|
Genomic Vision Société Anonyme
F:G09
|
$711.54K |
|
CL8 Holdings Ltd
AU:CL8
|
$711.19K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Emmaus Life Sciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -47,756,000 to -56,479,000, a change of -8,723,000.
- Net loss of 6,453,000 reduced equity.
- Other factors decreased equity by 2,270,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-6.45 Million | -11.43% |
| Other Changes | $-2.27 Million | -4.02% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Emmaus Life Sciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1999-12-31 | $0.00 | $0.02 | x |
| 2000-12-31 | $-0.94 | $0.02 | x |
| 2001-12-31 | $-7.54 | $0.02 | x |
| 2002-12-31 | $-10.20 | $0.02 | x |
| 2003-12-31 | $-16.66 | $0.02 | x |
| 2004-12-31 | $-187.87 | $0.02 | x |
| 2005-12-31 | $-201.12 | $0.02 | x |
| 2006-12-31 | $-139.54 | $0.02 | x |
| 2007-12-31 | $3440.30 | $0.02 | x |
| 2008-12-31 | $1499.86 | $0.02 | x |
| 2009-12-31 | $-956.98 | $0.02 | x |
| 2010-12-31 | $-2895.52 | $0.02 | x |
| 2011-12-31 | $-7335.58 | $0.02 | x |
| 2012-12-31 | $-8197.30 | $0.02 | x |
| 2013-12-31 | $-34.20 | $0.02 | x |
| 2014-12-31 | $-21.28 | $0.02 | x |
| 2015-12-31 | $-57.00 | $0.02 | x |
| 2016-12-31 | $-2.40 | $0.02 | x |
| 2017-12-31 | $9.68 | $0.02 | x |
| 2018-12-31 | $4.64 | $0.02 | x |
| 2019-12-31 | $-0.26 | $0.02 | x |
| 2020-12-31 | $-0.11 | $0.02 | x |
| 2021-12-31 | $-0.44 | $0.02 | x |
| 2022-12-31 | $-0.69 | $0.02 | x |
| 2023-12-31 | $-0.77 | $0.02 | x |
| 2024-12-31 | $-0.88 | $0.02 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Emmaus Life Sciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -38.75%
- • Asset Turnover: 0.71x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-52.56%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1999 | -400.00% | -200.00% | 2.00x | 1.00x | $-41.00K |
| 2000 | 0.00% | -55.14% | 2.92x | 0.00x | $-7.71K |
| 2001 | 0.00% | -124.03% | 2.63x | 0.00x | $-9.09K |
| 2002 | 0.00% | -147.37% | 7.43x | 0.00x | $-10.05K |
| 2003 | 0.00% | -2060.89% | 6.20x | 0.00x | $-137.47K |
| 2004 | 0.00% | 0.00% | 0.00x | 0.00x | $-237.17K |
| 2005 | 0.00% | 0.00% | 0.00x | 0.00x | $10.68K |
| 2006 | 0.00% | 0.00% | 0.00x | 0.00x | $-413.83K |
| 2007 | -61.26% | -1375.46% | 0.04x | 1.12x | $-3.81 Million |
| 2008 | -510.16% | -694.44% | 0.29x | 2.50x | $-5.48 Million |
| 2009 | 0.00% | -1217.28% | 0.60x | 0.00x | $-8.41 Million |
| 2010 | 0.00% | -1280.19% | 2.69x | 0.00x | $-7.75 Million |
| 2011 | 0.00% | -1188.71% | 2.02x | 0.00x | $-7.72 Million |
| 2012 | 0.00% | -2962.43% | 0.92x | 0.00x | $-2.10 Million |
| 2013 | 0.00% | -8332.62% | 0.09x | 0.00x | $-10.69 Million |
| 2014 | 0.00% | -1970.98% | 0.10x | 0.00x | $-2.49 Million |
| 2015 | 0.00% | -3376.02% | 0.18x | 0.00x | $-2.90 Million |
| 2016 | 0.00% | -6981.08% | 0.06x | 0.00x | $-5.92 Million |
| 2017 | -156.41% | -5535.25% | 0.02x | 1.34x | $-7.57 Million |
| 2018 | -238.72% | -729.66% | 0.26x | 1.28x | $-10.00 Million |
| 2019 | 0.00% | -241.04% | 0.38x | 0.00x | $-53.74 Million |
| 2020 | 0.00% | 5.84% | 0.39x | 0.00x | $1.90 Million |
| 2021 | 0.00% | -77.37% | 0.36x | 0.00x | $-13.80 Million |
| 2022 | 0.00% | -58.10% | 0.38x | 0.00x | $-7.28 Million |
| 2023 | 0.00% | -12.61% | 0.84x | 0.00x | $1.04 Million |
| 2024 | 0.00% | -38.75% | 0.71x | 0.00x | $-805.10K |
Industry Comparison
This section compares Emmaus Life Sciences Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Emmaus Life Sciences Inc (EMMA) | $-59.49 Million | -400.00% | N/A | $712.27K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |